Plasma leptin in postmenopausal women with coronary artery disease: Effect of transdermal 17β-estradiol and intermittent medroxyprogesterone acetate

Climacteric

Volumn 6, Issue 3, 2003, Pages 204-210

  Os, I ^a,b   Os, A ^b   Abdelnoor, M ^b   Larsen, A ^b   Birkeland, K ^c   Westheim, A ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coronary artery disease; Estradiol; Glucose; Insulin resistance; Leptin

Indexed keywords

APOLIPOPROTEIN A; C PEPTIDE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INTRADERMAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 0141504405     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/713605412     Document Type: Article

References (39)

1. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000;143:293-311
2. Kanda T, Ichikawa S, Sumnino H, et al. Positive correlation between circulating leptin levels and lipid lipoproteins in postmenopausal women administered hormone replacement therapy. Res Commun Mol Pathol Pharmacol 2000;107:179-85
3. Leyva F, Godsland IF, Ghatei M, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998;18:928-33
4. DeCourten M, Zimmet P, Hodge A, et al. Hyperleptinemia: the missing link in the metabolic syndrome? Diabet Med 1997;14:200-8
5. Haynes WG, Siwitz WI, Morgan AD, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-23
6. Rainwater DL, Comuzzie AG, Van de Berg JL, Mahaney MC, Blangero J. Serum leptin levels are independently correlated with two measures of HDL. Atherosclerosis 1997;132:237-43
7. Söderberg S, Ahrén B, Eliasson M, Johnson O, Olsson T. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999;245:533-43
8. Matsubara M, Chiba H, Maruoka S, Katayosa S. Elevated serum leptin concentrations in women with components of multiple risk factor clustering syndrome. J Atheroscler Thromb 2000;7:231-7
9. Gomez-Ambrosi J, Salvador J, Paramo JA, et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 2002;35:315-20
10. Söderberg S, Ahrén B, Jansson J-H, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999;246:409-18
11. Söderberg S, Ahrén B, Stegmayr B, et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999;30:328-37
12. Riad-Gabriel MG, Jinagouda SD, Sharma A, Boyadjian R, Saad MF. Changes in plasma leptin during menstrual cycle. Eur J Endocrinol 1998;139:528-31
13. Hickey MS, Israel RG, Gardiner SN, et al. Gender differences in serum leptin levels. Biochem Mol Med 1996;59:1-6
14. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5
15. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62
16. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women. J Am Med Assoc 2002;288:321-33
17. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-13
18. Os I, Hofstad AE, Brekke M, et al. The EWA (Estrogen in Women with Atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipoproteins. J Intern Med 2000;247:433-41
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations. Diabetologia 1985;28:412-19
20. Stumvoll M, Mitrakou A, Pimenta W, et al. Assessment of insulin secretion from oral glucose tolerance test in white patients with type 2 diabetes. Diabetes Care 2000;23:1440-1
21. Sokel RR, Rolf FJ. Biometry. New York: WH Freeman and Co, 1900:263
22. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:988-91
23. Zimmet PZ, Collins VR, de Courten MP, et al. Is there a relationship between serum leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius: Mauritius NCD Study Group. Int J Obes 1998;22:171-7
24. Saad MF, Khan A, Sharma A, et al. Physiological insulinemia acutely modulates plasma leptin. Diabetes 1998;47:544-9
25. Korbonits M, Trainer PJ, Little JA, et al. Leptin levels do not change acutely with food administration in normal and obese subjects, but are negatively correlated to pituitary-adrenal activity. Clin Endocrinol 1997;46:751-7
26. Dragogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M. Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes 1996;45:695-8
27. Couillard C, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S. Leptinemia is not a risk factor for ischemic heart disease in men. Diabetes Care 1998;21:782-6
28. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001;25:805-10
29. Mark AL, Sivitz WI. Uncoupling metabolism and coupling leptin to cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:881-3
30. Wallace AM, MacMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001;104:3052-6
31. Laivuori H, Koistinen HA, Karonen SL, Cacciotore B, Ylikorkala O. Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women. Hum Reprod 2001;16:1632-5
32. Hadji P, Görke K, Hars O, Bauer T, Emons G, Schulz K-D. The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women. Maturitas 2000;37:105-11
33. Konukoglu D, Serin Ö, Ercan M. Plasma leptin levels in obese and non-obese postmenopausal women before and after hormone replacement therapy. Maturitas 2000;36:203-7
34. Elbers JM, de Roo GW, Poop-Snijders C, et al. Effects of administration of 17β-oestradiol on serum leptin levels in healthy postmenopausal women. Clin Endocrinol 1999;51:449-54
35. Lavoie HB, Taylor AE, Sharpless JL, Anderson EJ, Strauss CC, Hall JE. Effects of short-term hormone replacement on serum leptin levels in postmenopausal women. Clin Endocrinol 1999;51:415-22
36. Kristensen K, Pedersen SB, Vetsergaard P, Mosekilde L, Richelsen B. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol 1999;163:55-62
37. Roussel AM, Bureau I, Favier M, Polansky MM, Bryden NA, Anderson RA. Beneficial effects of hormonal replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women. Maturitas 2002;42:63-9
38. Perera M, Sattar N, Petrie JR, et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2001;86:1140-3
39. Haffner SM, Mykkanen L, Stern MP. Leptin concentrations in women in the San Antonio Heart Study: effects of menopausal status and postmenopausal therapy. Am J Epidemiol 1997;146:581-5